SRRK

Scholar Rock Holding Corp. 10-Q Summary: Q1 2026

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Scholar Rock Holding Corp. is a global biopharmaceutical company focused on developing monoclonal antibodies for rare neuromuscular diseases, primarily Spinal Muscular Atrophy (SMA). The company's lead asset, apitegromab, is an anti-myostatin antibody. The company has no commercial product revenue and continues to incur significant operating losses while advancing clinical development and regulatory submissions.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by 41.2% to $105.5 million, driven by higher operating expenses and a $3.3 million loss on debt extinguishment.
• Operating Expenses: Total operating expenses rose 32.3% to $102.0 million.
  • R&D: Increased 6.4% to $51.8 million due to higher internal employee costs and drug supply manufacturing for apitegromab.
  • G&A: Increased 76.7% to $50.2 million, primarily due to investments in commercial infrastructure and headcount expansion.
• Debt Restructuring: The company terminated its existing loan agreement with Oxford Finance and entered a new $350 million facility with Blue Owl Capital. It drew $200 million in Q1 2026 to repay prior debt and fund operations.
• Equity Financing: Generated $111.8 million in net proceeds from the sale of common stock under its At-The-Market (ATM) program.
• Liquidity Position: Total cash, cash equivalents, and marketable securities increased by $112.4 million quarter-over-quarter.

Outlook, Guidance, and Risks

• Regulatory Status (Apitegromab):
  • U.S. FDA: The company resubmitted its Biologics License Application (BLA) in March 2026 after receiving a Complete Response Letter (CRL) in September 2025 related to a third-party fill-finish facility inspection. The resubmission included two fill-finish facilities and was accepted with a PDUFA action date of September 30, 2026.
  • EU EMA: A Marketing Authorisation Application (MAA) was validated in March 2025. A decision is anticipated in mid-2026, though the FDA CRL could impact the EMA review timeline.
• Commercialization: The company is building commercial infrastructure in anticipation of a potential launch in the U.S. and Europe upon approval.
• Pipeline Updates:
  • SRK-439: Phase 1 study in healthy volunteers is underway; topline data expected in H2 2026.
  • Subcutaneous Formulation: Phase 1 study for SC apitegromab completed with favorable bioavailability.
• Liquidity Outlook: Management believes existing cash and marketable securities ($479.9 million) are sufficient to fund operations into 2027. However, additional capital will be required to complete clinical development and commercialization.
• Key Risks:
  • Regulatory delays or denial of approval for apitegromab.
  • Manufacturing supply chain disruptions (reliance on third-party fill-finish facilities).
  • Need for additional financing to sustain operations beyond 2027.
  • Transition from "smaller reporting company" status, increasing compliance costs.

Investor Verification Checklist

• BLA Resubmission Acceptance: Confirm the FDA's acceptance of the March 2026 resubmission and the specific PDUFA date of September 30, 2026.
• Debt Covenants: Review the terms of the new Blue Owl facility, specifically the requirement to maintain a minimum unrestricted cash balance of 60% of outstanding principal.
• Manufacturing Resolution: Verify the status of the FDA inspection classification for the third-party fill-finish facility that triggered the previous CRL.
• Capital Runway: Assess the burn rate relative to the $479.9 million liquidity position to validate the "into 2027" funding estimate.
• Commercial Build-out: Monitor the pace of G&A spending increases as the company scales its commercial team ahead of a potential 2026 launch.